IMMU


Immunomedics, Inc. (IMMU): Analyst Phil Nadeau Provides Update From San Antonio Breast Cancer Symposium

Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.

J.P. Morgan Comments on Immunomedics, Inc. (IMMU) and Seattle Genetics (SGEN) Deal

This morning, Immunomedics, Inc. (NASDAQ:IMMU) and Seattle Genetics, Inc. (NASDAQ:SGEN) announced a in-licensing deal, where Seattle …

Two Biotech Stocks Analysts Are Talking About: Immunomedics, Inc. (IMMU), Ocular Therapeutix Inc (OCUL)

Immunomedics, Inc. Immunomedics, Inc. (NASDAQ:IMMU) shares jumped nearly 26% in Friday’s trading session, following the …

Company Update (NASDAQ:IMMU): Here’s Why Immunomedics, Inc. Shares Are Falling 27%

Immunomedics, Inc. (NASDAQ:IMMU) announced that it has priced an underwritten offering of 10,000,000 shares of …

Analysts Weigh In On Two Falling Biotechs: Adamis Pharmaceuticals Corp (ADMP), Immunomedics, Inc. (IMMU)

Analysts are weighing in on biotech firms Adamis Pharmaceuticals Corp (NASDAQ:ADMP) and Immunomedics, Inc. (NASDAQ:IMMU), as shares …